Denali Therapeutics Inc.
DNLI | NASDAQ
$20.47
+$0.75 (+3.80%)
At close: Sep 21, 2026, 4:00 PM ET
$20.55
+$0.08 (+0.39%)
Pre-market:
Sep 22, 2026, 6:21 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | 330.53M | 108.46M | 48.66M | 335.66M |
Cost of Revenue | 11.18M | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -11.18M | n/a | 330.53M | 108.46M | 48.66M | 335.66M |
Operating Income | -555.34M | -487.34M | -196.7M | -340.74M | -295.75M | 62.72M |
Interest Income | 42.9M | 64.64M | 51.51M | 14.77M | 4.6M | 9.24M |
Pretax Income | -512.44M | -422.71M | -145.19M | -325.97M | -291.16M | 71.96M |
Net Income | -512.54M | -422.77M | -145.22M | -325.99M | -290.58M | 71.14M |
Selling & General & Admin | 97.1M | 105.44M | 103.35M | 90.48M | 79.06M | 60.33M |
Research & Development | 418.78M | 396.44M | 423.88M | 358.73M | 265.35M | 212.62M |
Other Expenses | 28.28M | -14.54M | n/a | n/a | n/a | n/a |
Operating Expenses | 544.16M | 487.34M | 527.23M | 449.21M | 344.41M | 272.94M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 555.34M | 487.34M | 527.23M | 449.21M | 344.41M | 272.94M |
Income Tax Expense | 102K | 68K | 30K | 21K | -575K | 823K |
Shares Outstanding (Basic) | 175.46M | 164.47M | 137.37M | 125.53M | 121.52M | 108.97M |
Shares Outstanding (Diluted) | 175.46M | 164.47M | 137.37M | 125.53M | 121.52M | 112.7M |
EPS (Basic) | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 | 0.65 |
EPS (Diluted) | -2.97 | -2.57 | -1.06 | -2.60 | -2.39 | 0.63 |
EBITDA | -497.63M | -492.89M | -128.47M | -315.59M | -282.56M | 71.25M |
EBIT | -512.44M | -501.88M | -145.19M | -325.97M | -291.16M | 62.72M |
Depreciation & Amortization | 14.81M | 8.99M | 16.73M | 10.38M | 8.59M | 8.53M |
Add to Watchlist
Select watchlists to add or remove DNLI